We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.
- Authors
Weimer LE; Fragola V; Floridia M; Guaraldi G; Ladisa N; Francisci D; Bellagamba R; Degli Antoni A; Parruti G; Giacometti A; Manconi PE; Vivarelli A; D'Ettorre G; Mura MS; Cicalini S; Preziosi R; Sighinolfi L; Verucchi G; Libertone R; Tavio M
- Abstract
<bold>Objectives: </bold>To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine.<bold>Methods: </bold>We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection.<bold>Results: </bold>Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number <50 copies/mL was 4.1 months (95% CI 3.5-4.6) in non-coinfected patients and 3.9 months (95% CI 3.3-4.5) in coinfected patients (hazard ratio 1.039, 95% CI 0.761-1.418, P = 0.766, log-rank test). The risk of developing new grade 3-4 hepatic adverse events was significantly higher in coinfected patients (hazard ratio 1.779, 95% CI 1.123-2.817, P = 0.009). The two groups of coinfected and non-coinfected patients had similar rates of interruption of any baseline drug (hazard ratio 1.075, 95% CI 0.649-1.781, P = 0.776) and of raltegravir (hazard ratio 1.520, 95% CI 0.671-3.447, P = 0.311). Few AIDS-defining events and deaths occurred.<bold>Conclusions: </bold>Viroimmunological response to regimens based on raltegravir and other recent anti-HIV inhibitors is not negatively affected by coinfection with HBV or HCV. Liver toxicity, either pre-existing or new, is more common in coinfected patients, but with no increased risk of treatment interruption.
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2013, Vol 68, Issue 1, p193
- ISSN
0305-7453
- Publication type
journal article
- DOI
10.1093/jac/dks341